Please upgrade your browser.
The authors discuss a pigmented perivascular epithelioid cell tumour of the kidney in a woman with clinically indicated tuberous sclerosis and suggest that this type of tumour be differentiated from clear cell renal cell carcinoma or malignant melanoma.
Can renal oncocytoma be distinguished from chromophobe renal cell carcinoma by the presence of fibrous capsule
Average thickness of capsule in CRCCs was 337.7 microm, and 115.4 microm in renal oncocytomas, but the median was not statistically significant (P = 0.198). Studies with a larger number of cases are needed to conclude if this characteristic could be a lowcost, reliable microscopic feature in differentiating between CRCC and renal oncocytoma.
Residents of a northern New Jersey town that was once home to a DuPont munitions plant are taking on the chemical giant and making sure their voices are heard after a cancer cluster was uncovered.
A Metairie man says he's lucky, even though he has a serious form of cancer. First, he's lucky for the reason he initially went to the doctor, and second, because he lives right here in this area, where a groundbreaking treatment was pioneered.
Renal cell carcinoma represents 3% of all cancer cases but has a significant death rate associated with it: Its estimated that there will be 60,000 new cases this year and 16,000 deaths from kidney cancer. The risk factors associated with kidney cancer include smoking, obesity, hypertension, and some occupational exposure.
Patients and family members should be encouraged to learn as much as they can about RCC so that they are in a better position to participate in treatment planning. An empowered, knowledgeable patient is more likely to stick with the therapeutic regimen even through the worst bouts of physical and emotional distress.
This years biggest medical advances are changing the face and future of your health. Heres what you need to know now.
Unfortunately, for renal cell carcinoma (RCC), early detection is almost impossible. At least 40 per cent of the patients are at an advanced stage of the disease when they are diagnosed.
Good response to second-line bevacizumab and interferon-[alpha] in a sunitinib-refractory patient with metastatic renal cell carcinoma
In clinical practice, sunitinib and bevacizumab are reserved for firstline treatment, but despite various guidelines, optimal treatment is still uncertain. The authors present, for the first time, a case of a good response to secondline bevacizumab and interferonalpha in a patient who failed classical sunitinib treatment.
Co-administration of cG250 and IL-2 or IFN-.alpha. for treating cancer such as renal cell carcinomas
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN).
|Powered by NeonCRM|